Bajaj HealthCare Limited (BAJAJHCARE.NS)
INR 515.9
(-1.0%)
INR 515.9
(-1.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 406.23 Million INR | -29.67% |
| 2022 | 1.12 Billion INR | -9.82% |
| 2021 | 1.21 Billion INR | -16.08% |
| 2020 | 1.38 Billion INR | 179.28% |
| 2019 | 554.87 Million INR | 20.74% |
| 2018 | 459.66 Million INR | 4.63% |
| 2017 | 394.93 Million INR | 25.86% |
| 2016 | 310.55 Million INR | 8.45% |
| 2015 | 313.38 Million INR | 3.44% |
| 2014 | 287.67 Million INR | 48.01% |
| 2013 | 194.34 Million INR | 50.86% |
| 2012 | 129.01 Million INR | 13.76% |
| 2011 | 113.44 Million INR | -22.58% |
| 2010 | 147.82 Million INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 245.04 Million INR | 212.19% |
| 2023 Q1 | 219.62 Million INR | 11.01% |
| 2023 Q2 | 201.67 Million INR | -8.17% |
| 2023 Q3 | 203.34 Million INR | 0.83% |
| 2023 Q4 | 160.34 Million INR | -21.15% |
| 2023 FY | - INR | -29.67% |
| 2022 Q4 | 197.84 Million INR | -31.06% |
| 2022 Q1 | 265.13 Million INR | 2.71% |
| 2022 Q2 | 334.47 Million INR | 26.15% |
| 2022 Q3 | 286.99 Million INR | -14.19% |
| 2022 FY | - INR | -9.82% |
| 2021 FY | - INR | -16.08% |
| 2021 Q2 | 290.83 Million INR | -14.9% |
| 2021 Q4 | 258.13 Million INR | -16.81% |
| 2021 Q3 | 310.28 Million INR | 6.69% |
| 2021 Q1 | 341.77 Million INR | -7.17% |
| 2020 Q2 | 344.03 Million INR | 31.07% |
| 2020 FY | - INR | 179.28% |
| 2020 Q1 | 262.47 Million INR | 37.71% |
| 2020 Q4 | 368.17 Million INR | -19.64% |
| 2020 Q3 | 458.16 Million INR | 33.17% |
| 2019 Q1 | 93.87 Million INR | -30.06% |
| 2019 Q2 | 91.16 Million INR | -2.88% |
| 2019 FY | - INR | 20.74% |
| 2019 Q3 | 137.4 Million INR | 50.72% |
| 2019 Q4 | 190.6 Million INR | 38.72% |
| 2018 Q1 | 198.07 Million INR | 72.69% |
| 2018 Q4 | 134.22 Million INR | -0.0% |
| 2018 Q3 | 134.22 Million INR | 40.84% |
| 2018 Q2 | 95.29 Million INR | -51.89% |
| 2018 FY | - INR | 4.63% |
| 2017 Q1 | 83.42 Million INR | 6.42% |
| 2017 Q3 | 115.35 Million INR | 38.28% |
| 2017 Q2 | 83.42 Million INR | 0.0% |
| 2017 FY | - INR | 25.86% |
| 2017 Q4 | 114.7 Million INR | -0.57% |
| 2016 FY | - INR | 8.45% |
| 2016 Q4 | 78.38 Million INR | 7.02% |
| 2016 Q3 | 73.24 Million INR | 2.09% |
| 2016 Q2 | 71.74 Million INR | 0.0% |
| 2016 Q1 | 71.74 Million INR | -3.47% |
| 2015 Q1 | 83.64 Million INR | 0.0% |
| 2015 FY | - INR | 3.44% |
| 2015 Q3 | 48.36 Million INR | -42.18% |
| 2015 Q4 | 74.33 Million INR | 53.7% |
| 2015 Q2 | 83.64 Million INR | 0.0% |
| 2014 FY | - INR | 48.01% |
| 2013 FY | - INR | 50.86% |
| 2012 FY | - INR | 13.76% |
| 2011 FY | - INR | -22.58% |
| 2010 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Amrutanjan Health Care Limited | 681.59 Million INR | 40.399% |
| Biofil Chemicals and Pharmaceuticals Limited | 12.99 Million INR | -3025.869% |
| Caplin Point Laboratories Limited | 6.18 Billion INR | 93.431% |
| FDC Limited | 3.38 Billion INR | 88.0% |
| Gufic Biosciences Limited | 1.48 Billion INR | 72.56% |
| Hikal Limited | 2.69 Billion INR | 84.911% |
| Ind-Swift Laboratories Limited | 6.86 Billion INR | 94.08% |
| IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | 84.415% |
| Kilitch Drugs (India) Limited | 287.42 Million INR | -41.337% |
| Medico Remedies Limited | 129.09 Million INR | -214.684% |
| Nectar Lifesciences Limited | 1.53 Billion INR | 73.545% |
| Par Drugs and Chemicals Limited | 228.17 Million INR | -78.039% |
| RPG Life Sciences Limited | 1.28 Billion INR | 68.3% |
| Sequent Scientific Limited | 549.8 Million INR | 26.112% |
| Shilpa Medicare Limited | 2.58 Billion INR | 84.303% |
| Sigachi Industries Limited | 883.39 Million INR | 54.014% |
| Themis Medicare Limited | 562.6 Million INR | 27.794% |
| Unichem Laboratories Limited | 742.35 Million INR | 45.277% |
| Venus Remedies Limited | 711.8 Million INR | 42.928% |
| Wanbury Limited | 985.49 Million INR | 58.778% |
| ZIM Laboratories Limited | 462.09 Million INR | 12.088% |
| Lupin Limited | 36.96 Billion INR | 98.901% |
| Innova Captab Limited | 1.66 Billion INR | 75.65% |
| Ind-Swift Limited | 1.06 Billion INR | 61.858% |
| Aurobindo Pharma Limited | 61.78 Billion INR | 99.343% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | 114.396% |
| AstraZeneca Pharma India Limited | 2.35 Billion INR | 82.763% |
| Mangalam Drugs & Organics Limited | 174.94 Million INR | -132.208% |
| Morepen Laboratories Limited | 1.72 Billion INR | 76.463% |
| Laurus Labs Limited | 8 Billion INR | 94.926% |
| Aarti Drugs Limited | 3.24 Billion INR | 87.495% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | 94.081% |
| Alembic Limited | 1.11 Billion INR | 63.61% |
| Alembic Pharmaceuticals Limited | 9.61 Billion INR | 95.776% |
| Glenmark Pharmaceuticals Limited | 11.34 Billion INR | 96.419% |
| Vaishali Pharma Limited | 31.71 Million INR | -1181.063% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | 89.609% |
| Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | -25.591% |
| Jubilant Pharmova Limited | 8 Billion INR | 94.926% |
| Eris Lifesciences Limited | 6.98 Billion INR | 94.185% |
| Windlas Biotech Limited | 781.72 Million INR | 48.033% |
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 99.706% |
| Lincoln Pharmaceuticals Limited | 1.34 Billion INR | 69.759% |
| Orchid Pharma Limited | 1.41 Billion INR | 71.375% |
| Albert David Limited | 1.04 Billion INR | 61.141% |
| Hester Biosciences Limited | 539.47 Million INR | 24.697% |
| Sakar Healthcare Limited | 393.26 Million INR | -3.298% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | 91.314% |
| Procter & Gamble Health Limited | 3.07 Billion INR | 86.786% |
| Divi's Laboratories Limited | 25.43 Billion INR | 98.403% |
| Mankind Pharma Limited | 28.09 Billion INR | 98.554% |
| Neuland Laboratories Limited | 4.74 Billion INR | 91.444% |
| J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | 95.648% |
| Zydus Lifesciences Limited | 56.22 Billion INR | 99.277% |
| Wockhardt Limited | 1.08 Billion INR | 62.385% |
| Bal Pharma Limited | 345.59 Million INR | -17.548% |
| Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 99.54% |
| Bliss GVS Pharma Limited | 1.47 Billion INR | 72.533% |
| Alkem Laboratories Limited | 24.19 Billion INR | 98.321% |
| Valiant Laboratories Limited | 12.73 Million INR | -3088.932% |
| Ajanta Pharma Limited | 12.56 Billion INR | 96.767% |
| Bafna Pharmaceuticals Limited | 114.58 Million INR | -254.536% |
| Aarey Drugs & Pharmaceuticals Limited | 45.16 Million INR | -799.453% |
| Granules India Limited | 8.6 Billion INR | 95.278% |
| Medicamen Biotech Limited | 245.66 Million INR | -65.366% |
| Ipca Laboratories Limited | 13.29 Billion INR | 96.945% |
| Brooks Laboratories Limited | 41.72 Million INR | -873.538% |
| Syncom Formulations (India) Limited | 430.27 Million INR | 5.587% |
| Piramal Enterprises Limited | -3.86 Billion INR | 110.521% |
| Torrent Pharmaceuticals Limited | 35 Billion INR | 98.84% |
| NATCO Pharma Limited | 18.79 Billion INR | 97.839% |
| Suven Life Sciences Limited | -992.78 Million INR | 140.919% |
| Krebs Biochemicals & Industries Limited | -82.72 Million INR | 591.059% |
| Strides Pharma Science Limited | 3.76 Billion INR | 89.209% |
| Indoco Remedies Limited | 2.64 Billion INR | 84.653% |
| Alpa Laboratories Limited | 229.96 Million INR | -76.655% |
| Lasa Supergenerics Limited | -65.08 Million INR | 724.213% |
| Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 110.887% |